OTCMKTS:SNPHY Santen Pharmaceutical (SNPHY) Stock Price, News & Analysis → This Weight Loss Company Can't Make Enough Product (From Behind the Markets) (Ad) Free SNPHY Stock Alerts $10.25 0.00 (0.00%) (As of 06/17/2024 ET) Add Compare Share Share Today's Range$10.25▼$10.2550-Day Range$9.12▼$10.7752-Week Range$8.08▼$10.85Volume29 shsAverage Volume4,432 shsMarket CapitalizationN/AP/E Ratio0.10Dividend Yield471.21%Price TargetN/A Stock AnalysisStock AnalysisChartFinancialsSEC FilingsShort InterestStock AnalysisChartFinancialsSEC FilingsShort Interest Get Santen Pharmaceutical alerts: Email Address Ad Behind the MarketsAre you prepared for a Chinese "invasion?"Recently declassified documents show that while the U.S has been distracted in the Middle East... China had been studying our every move... And preparing themselves for not only an armed conflict with the United StatesHere are 4 steps you can take RIGHT NOW >>> About Santen PharmaceuticalSanten Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension. The company also offers sepetaprost, a prostaglandin analogue eye drop drug that is in phase 3 of clinical trials; and latanoprost, an ophthalmic emulsion of a prostaglandin F2a derivative which is filed for marketing approval for the treatment of glaucoma and ocular hypertension. In addition, it provides cyclosporin, an ophthalmic emulsion for the treatment of vernal keratoconjunctivitis; and diquafosol sodium for dry eye treatment. Further, the company develops olodaterol hydrochloride, a ß2 receptor agonist that is in phase 1/2a for the treatment of A dry eye treatment dry eye; sirolimus, an ophthalmic suspension which is in phase 2a for the treatment of 4 Fuchs endothelial corneal dystrophy and meibomian gland dysfunction; epinastine hydrochloride, a histamine H1 receptor antagonist filed for marketing approval for the treatment of allergic conjunctivitis; atropine sulfate, a non-selective muscarinic antagonist that is in phase 2/3 clinical trials for myopia treatment; and AFDX0250BS, an selective muscarinic M2 antagonist which is in phase 2a for the treatment of myopia. Additionally, it offers ursodeoxycholic acid that is in phase 2a of clinical trial for the treatment of presbyopia; and oxymetazoline hydrochloride, a direct-acting alpha adrenergic receptor agonist which is in phase 3 for treatment of ptosis. The company was founded in 1890 and is headquartered in Osaka, Japan.Read More SNPHY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SNPHY Stock News HeadlinesMay 17, 2024 | investorplace.comSNPHY Stock Earnings: Santen Pharmaceutical Reported Results for Q4 2023May 9, 2024 | markets.businessinsider.comSanten Pharmaceutical earnings preview: what to expectApril 23, 2024 | morningstar.comSanten Pharmaceutical Co LtdApril 20, 2024 | wsj.comSanten Pharmaceutical Co. Ltd. ADRDecember 27, 2023 | finance.yahoo.comSanten Pharmaceutical Co. Ltd. (JP3336000009.SG)October 4, 2023 | msn.comSanten Pharmaceutical Co. - ADR (SNPHY) Price Target Increased by 7.52% to 10.41August 9, 2023 | seekingalpha.comSNPHY Santen Pharmaceutical Co., Ltd.August 4, 2023 | msn.comSanten Pharmaceutical Co., Ltd. reports Q1 resultsJuly 19, 2023 | benzinga.comHarrow Acquires Santen's Branded Ophthalmic PortfolioJuly 19, 2023 | businesswire.comSanten Agrees to Licensing Agreements and Asset Transfer for its Pharmaceutical Products in North AmericaMay 11, 2023 | msn.comSanten Pharmaceutical Co. reports FY resultsAugust 4, 2022 | markets.businessinsider.comSanten Pharmaceutical is about to announce its earnings — here's what to expectJuly 23, 2022 | marketwatch.comOphthalmology Equipment Market Demand Analysis & Opportunity Outlook 2029May 24, 2022 | marketwatch.comOphthalmology Equipment Market Demand, Opportunity, Outlook, Trends, Revenue, Future Growth Opportunities By2029December 2, 2021 | investing.comSanten Pharmaceutical Co (SNPHY)November 11, 2021 | seekingalpha.comSanten Pharmaceutical Co., Ltd. 2021 Q2 - Results - Earnings Call PresentationSee More Headlines Receive SNPHY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Santen Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - General Sub-IndustryN/A Current SymbolOTCMKTS:SNPHY CUSIPN/A CIK1501108 Webwww.santen.com Phone(167) 664-8621FaxN/AEmployees4,144Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio0.10 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Takeshi Ito (Age 65)President, CEO & Representative Director Mr. Kazuo KoshijiChief Financial Officer & Chief Risk OfficerMs. Rie NakajimaCOO & Corporate OfficerMr. Minori HaraChief Digital & Information OfficerMs. Kaori ItagakiGeneral Manager of Investor Relations GroupMs. Mika MasunariGeneral Counsel & Chief Compliance OfficerMs. Nobuko KatoChief Communications OfficerMr. Satoshi Suzuki (Age 61)Senior Corporate Officer & Head of Corporate Development Division & Director Mr. Shinichi TeramachiCorporate Officer, Head of Sales Department & Japan Sales and Marketing DivisionMr. Ippei KuriharaCorporate Officer and Head of Marketing Department, Japan Business, Japan Sales & Marketing DivisionMore ExecutivesKey CompetitorsAstraZenecaOTCMKTS:AZNCFDaiichi SankyoOTCMKTS:DSNKYDechra PharmaceuticalsOTCMKTS:DCHPFJCR PharmaceuticalsOTCMKTS:JCRRFKyowa KirinOTCMKTS:KYKOFView All Competitors SNPHY Stock Analysis - Frequently Asked Questions How have SNPHY shares performed in 2024? Santen Pharmaceutical's stock was trading at $9.85 at the beginning of 2024. Since then, SNPHY stock has increased by 4.1% and is now trading at $10.25. View the best growth stocks for 2024 here. Is Santen Pharmaceutical a good dividend stock? Santen Pharmaceutical (OTCMKTS:SNPHY) pays an annual dividend of $48.30 per share and currently has a dividend yield of 1.47%. The dividend payout ratio is 46.34%. This payout ratio is at a healthy, sustainable level, below 75%. How do I buy shares of Santen Pharmaceutical? Shares of SNPHY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:SNPHY) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredUnexpected twist to Trump’s trialUnexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredInflation Is Robbing You Blind! Here’s How to Fight Back!Quietly, inflation has reduced your purchasing power by 29.4% since 2014. So something that cost $100 in 20...American Alternative | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Santen Pharmaceutical Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Santen Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.